{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Table 1:', 'Schedule of Events: Screening and Treatment Period', 'Cycles 1 through 16 (cycle length = 6 weeks)', 'Day', 'Day', 'Study Procedure', 'Screening Visit X', '1', 'Day 8', 'Day 15', '22', 'Day 29', 'Day 42', 'Screening1', 'Inclusion/exclusion', 'X', 'Informed consent\u00b2', 'X', 'Genomics sub-study informed', 'X', 'consent (optional)', 'Medical history and demographics', 'X', 'Electrocardiogram', 'X', 'Performance status', 'X', 'Tumor tissue sample', 'X', 'Randomization', 'X', 'Treatment:', 'Cemiplimab (experimental)', 'X\u00b3', 'X', 'Pemetrexed', 'X\u00b3', 'X', 'Topotecan', 'Days', 'Days', '1-5\u00b3', '22-26', 'Irinotecan', 'X\u00b3', 'X', 'X', 'X', 'Gemcitabine', 'X\u00b3', 'X', 'X', 'X', 'Vinorelbine', 'X\u00b3', 'X', 'X', 'X', 'Concomitant medications', 'X', 'X', 'X', 'X', 'X', 'X', 'Efficacy (Radiologic):', 'CT scan and/or MRI', 'X', 'X', '(cycles 1-4, 6, 8, 10, 12, 14,', 'and 16)', 'Safety:', 'Vital signs4', 'X', 'X', 'Only for', 'Only for', 'X', 'Only for gemcitabine', 'gemcitabine,', 'irinotecan', 'and vinorelbine', 'irinotecan,', 'and', 'vinorelbine', 'Weight and height (height at', 'X', 'X6', 'screening only)5', 'Complete physical examination7', 'X', 'Limited physical examination8', 'X', 'Regeneron Pharmaceuticals, Inc.', 'Page 53 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Cycles 1 through 16 (cycle length = 6 weeks)', 'Day', 'Day', 'Study Procedure', 'Screening Visit X', '1', 'Day 8', 'Day 15', '22', 'Day 29', 'Day 42', 'Adverse events', '<', 'Continuous Monitoring for Adverse Events', 'Laboratory Testing:', 'Hematology', 'X', 'X6,9', 'Only for', 'Only for', 'X', 'Only for gemcitabine', 'gemcitabine', 'irinotecan', 'and vinorelbine', 'and', 'vinorelbine', 'Blood chemistry', 'X', 'X6,9', 'Only for', 'X', 'irinotecan', 'Prothrombin time, Activated partial', 'X', 'thromboplastin time', 'TSH (with reflex T3, free T4)', 'X', 'HBV, HCV, HIV', 'X', 'Pregnancy test for WOCBP10', 'X', 'Urinalysis', 'X', 'PK, ADA, Biomarkers', 'PK, ADA, soluble biomarkers, and PBMC are collected from patients randomized to cemiplimab', 'PK', 'X11', 'ADA sample', 'X12', 'Soluble biomarkers', 'X', '(serum/plasma1\u00b3', 'PBMC only for cemiplimab arm', 'X14', '(optional)', 'Genomic DNA sample (optional', 'X', 'sub-study)', 'Quality of Life', 'EORTC QLQ-C30', 'X', 'X6,15', 'Regeneron Pharmaceuticals, Inc.', 'Page 54 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '7.1.2.', 'Footnotes for the Schedule of Events Table for Screening and Treatment', '1.', 'Patients who fail screening may be screened one additional time and an ICF will need to be', 'signed at the re-screen. Some procedures may not need to be repeated if they were previously', 'completed within 28 days prior to cycle 1 day 1.', '2. Informed consent must be provided before the initiation of screening procedures, and must', 'be obtained within 45 days prior to cycle1/day 1. All screening assessments must be', 'performed within 28 days prior to cycle 1/day 1. Assessments performed as part of standard', 'of care that fall within the screening window, but before informed consent is obtained, may', 'be used for screening and need not be repeated for enrollment eligibility.', '3. The first dose should be administered no later than 5 days after randomization (except for', 'patient assigned to pemetrexed, for whom the first dose of pemetrexed may be given no later', 'than 10 days after randomization due to need for folate premedication for at least 5 days in', 'the 7 day period preceding the first dose of pemetrexed, as per Section 8.1.2.1).', '4. Only for patients assigned to cemiplimab: At cycle 1 day 1 and cycle 1 day 22, vital signs', 'will be collected prior to infusion, and approximately 30 minutes after the completion of the', 'infusion. For all other cemiplimab infusions, vital signs are collected prior to infusion, and', 'approximately 15 minutes after the completion of the infusion. The allowable window for', 'each specified time point is 10 minutes.', '5. For the IC options, doses are weight-based. For cycle 1/day 1, the investigator should use', 'screening height and weight to calculate dose, but cycle 1/day 1 weight is also allowed to be', 'used, per investigator discretion. Weight is measured at start of each cycle. If there is a', '>10% change in weight, the IC chemotherapy dose should be re-calculated.', '6. If cycle 1/day 1 is within 72 hours of screening, this assessment does not need to be repeated', 'at cycle 1/day 1.', '7. Complete physical examination includes head and neck, lungs, heart, abdomen, lymph nodes,', 'extremities, and skin. A brief neurologic examination should also be performed. The exam', '(and measurement of weight) may be performed 72 hours prior to study treatment.', '8. Limited physical exam includes lungs, heart, abdomen, and skin. The exam (and easement', 'of weight) may be performed 72 hours prior to study treatment.', '9. Hematology and chemistry samples may be obtained 72 hours prior to study treatment.', '10. Pre-dose serum \u00df-human chorionic gonadotropin (HCG) at screening up to 72 hours prior to', 'first administration. Subsequent predose pregnancy tests (up to 72 hours before the dose)', 'may be urine \u00df-HCG. Serum pregnancy test and urine pregnancy test are requirements for', 'women of child bearing potential only. If surgical procedure for sterility was done <30 days', 'prior to signing ICF, serum pregnancy test must still be performed.', '11. The PK samples are collected predose (pre-infusion) and at the end of infusion on day 1 of', 'cycle 1. PK samples are collected at pre-infusion and at the end of infusion on day 1 of', 'cycles 2 through 6, 7, 9, 11, 13, and 15. The PK samples are to be obtained only from patients', 'randomized to receive cemiplimab. \"End of infusion\" includes up to within 10 minutes after', 'completion of the infusion.', 'Regeneron Pharmaceuticals, Inc.', 'Page 55 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}